Advertisement

Topics

Cyberonics Incorporated Company Profile

13:49 EDT 24th September 2017 | BioPortfolio

Cyberonics, Inc. (NASDAQ: CYBX) pioneered the Vagus Nerve Stimulation (VNS Therapy™) System. Founded in 1987 to design, develop and market implantable medical devices for the treatment of epilepsy and other debilitating neurological disorders, Cyberonics has emerged as a leader in the neuromodulation industry. The VNS Therapy System uses a surgically implanted medical device that delivers electrical pulsed signals to the vagus nerve in the left side of the neck. This therapy has proven effective in significantly reducing the number and/or intensity of seizures in many people suffering from epilepsy and has the potential for use in the treatment of other inadequately treated, chronic disorders. In 1997, Cyberonics received approval from the Food and Drug Administration (FDA) to market VNS Therapy for the treatment of epilepsy. Since that time, more than 32,000 patients worldwide have been implanted with the device. These patients have accumulated in excess of 100,000 patient years of experience using this life-enhancing therapy. The remarkable success of VNS Therapy in the treatment of epilepsy has served as a platform for continued innovation. On July 15, 2005 , after seven years of extensive study and clinical trials, VNS Therapy was approved by the FDA as a long-term adjunctive treatment for treatment-resistant depression. It is also at various levels of study as a potential treatment for other chronic disorders, including anxiety, Alzheimer’s, bulimia, and migraine headaches. Headquartered in Houston , Texas , Cyberonics has additional offices in Brussels , Belgium . The Company markets the VNS Therapy system in selected markets worldwide.

Location

The Cyberonics Building
100 Cyberonics Boulevard
Houston
TX
77058
United States of America

Contact

Phone: 1 (888) 867-7846
Fax: (281) 218-9332


News Articles [7 Associated News Articles listed on BioPortfolio]

Cyberonics to Present at Citi 2012 Global Health Care Conference

HOUSTON, Feb. 10, 2012 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced it will participate i...

Cyberonics to Report Fiscal Year 2012 Third Quarter Results and Host Conference Call on February 24, 2012

HOUSTON, Feb. 1, 2012 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today announced that the company will report financial results for the third quarter ended January 27, 2012, of its fiscal year end...

Reese Terry, Founder and Former CEO of Cyberonics, Joins ElectroCore Board of Directors

MORRIS PLAINS, N.J., Jan. 4, 2013 /PRNewswire/ -- ElectroCore®, a company dedicated to developing effective, non-invasive Vagal Nerve Stimulation (nVNS) therapies for serious headac...

Cyberonics Announces Expansion of Share Repurchase Program By An Additional One Million Shares

HOUSTON, Dec 5, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX) today announced that, following substantial completion of its prior share repurchase program, its board of directors has appr...

Cyberonics Reports Fiscal 2014 First Quarter Results

HOUSTON, Aug. 22, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today announced results for the quarter ended July 26, 2013.  Quarterly highlights Operating results for the first q...

Neurostimulation Devices Market Global Briefing 2017 Including: Microelectrodes, Neurostimulators, Spinal Cord Stimulators, Deepbrain Stimulators, Gastric Electrical Stimulator, Transcranial Magnetic Stimulators, And Sacral And Vagus Nerve Stimulators.Cov

The global neurostimulation devices market was estimated to be around $4.02 billion as of 2016. The global neurostimulation devices made up around 46% of the overall neurology devices market in 2016. ...

Milestone Scientific Announces Children's Hospital of Pittsburgh to use The Wand(R) Computer Assisted Anesthesia System for Pediatric Patients

LIVINGSTON, NJ --(Marketwired - September 14, 2017) - Milestone Scientific Inc. (NYSE American: MLSS) (NYSE MKT: MLSS), a medical company that develops and commercializes a growing portfolio of propri...

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

AERODYNAMIC PROPERTIES AND IN SILICO DEPOSITION OF MELOXICAM POTASSIUM INCORPORATED IN A CARRIER-FREE DPI PULMONARY SYSTEM.

Dry powder inhalers (DPIs) have been among the fastest developing inhaler forms in the past decades. Researches are focusing on the formulation of carrier-free powders to obtain a higher deep-lung dep...

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Long Term Observational Study of a Vagal Nerve Stimulation Device in Crohn's Disease

This will be an open label multicenter study of the safety and efficacy of an active implantable VNS device in patients with Crohn's Disease.

Autonomic Regulation Therapy in Heart Failure With Preserved Ejection Fraction

The ANTHEM-HFpEF Study is designed to demonstrate the safety and efficacy of vagus nerve stimulation (VNS) with the Cyberonics VNS Therapy System for the treatment of subjects with symptom...

Companies [39 Associated Companies listed on BioPortfolio]

Cyberonics Sorin

Cyberonics, Inc. is a medical device company with core expertise in neuromodulation. The company developed and markets the VNS Therapy® System, which is FDA-approved for the tr...

Cyberonics, Inc.

Cyberonics, Inc. (NASDAQ:CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy System, which is FDA...

Cyberonics Incorporated

Cyberonics, Inc. (NASDAQ: CYBX) pioneered the Vagus Nerve Stimulation (VNS Therapy™) System. Founded in 1987 to design, develop and market implantable medical devices for the treatment of epilepsy a...

PRAECIS PHARMACEUTICALS INCORPORATED

PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.PRAECIS has...

LivaNova PLC

LivaNova PLC is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical devic...

More Information about "Cyberonics Incorporated" on BioPortfolio

We have published hundreds of Cyberonics Incorporated news stories on BioPortfolio along with dozens of Cyberonics Incorporated Clinical Trials and PubMed Articles about Cyberonics Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cyberonics Incorporated Companies in our database. You can also find out about relevant Cyberonics Incorporated Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Epilepsy
Epilepsy is defined as a disorder of brain function characterized by recurrent seizures that have a sudden onset.  (Oxford Medical Dictionary).  A seizure is caused by a sudden burst of excess electrical activity in the brain, causing a tempora...

Medical Devices
The role of medical devices in healthcare is essential.  The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare.  Covering a wide range of products, from simple bandages to the...


Corporate Database Quicklinks



Searches Linking to this Company Record